RecruitingPhase 3NCT06846281
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Sponsor: Novartis Pharmaceuticals
Fargo, ND · +43 more sites
Multiple Sclerosis clinical trials in Fargo, ND
1 recruiting multiple sclerosis studies with a site in Fargo, ND.
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.